Latest Intellectual Property News

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Rubicon Water Limited posted its strongest revenue since IPO at $69.1 million in FY25, driven by robust growth in the US and EMEA markets. Despite a $7 million net loss, the company improved cash flow and reduced debt, positioning itself for further global irrigation automation expansion.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Carbonxt Group Limited has announced a fully underwritten non-renounceable entitlement offer of Loyalty Options to eligible shareholders, aiming to raise approximately $697,772 to support its new Activated Carbon manufacturing facility in Kentucky. The offer provides shareholders with one Loyalty Option for every six shares held, exercisable at $0.07 within three years.

EOS has reported a 126% increase in its contract backlog to $307 million in 1H 2025, driven by strong demand for its defence and space technologies despite a revenue decline. The company secured a landmark €71.4 million high energy laser weapon export contract and continues to strengthen its balance sheet.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Orbital Corporation reveals a strategic pivot amid evolving US drone policies, with a new management team driving growth beyond Boeing Insitu. FY25 guidance shows revenue decline but promising new contracts.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.

IPH Limited reported a 13.2% rise in net profit after tax to $68.8 million for FY25, driven by strategic acquisitions in Canada and organic growth across Asia-Pacific. Revenue surged 16.5% to $710.3 million despite inflationary pressures and operational challenges.

Li-S Energy Limited reported a $6.41 million net loss for FY25 while making significant strides in commercialising its lithium-sulfur battery technology, including commissioning new production facilities and securing key strategic partnerships.